Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss.
GLP-1 受體激動劑可能對未受監控的體重減輕過於有效的警示。
Obes Rev 2024-04-22
GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
GPR119激動劑用於2型糖尿病:既往失敗和對預臨床和早期候選藥物的未來希望。
Expert Opin Investig Drugs 2024-03-18
Problematic Pharmacokinetics: A Case of Recurrent Pancreatitis Post Discontinuation of a Glucagon-Like Peptide 1 Receptor Agonists.
問題藥物動力學:停用 Glucagon-Like Peptide 1 受體激動劑後反覆發作的胰臟炎案例。
J Pharm Pract 2024-08-07
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes.
評估新型 GLP-1 受體激動劑在 2 型糖尿病中的治療和毒理特徵。
Expert Opin Drug Metab Toxicol 2024-09-13